MX2021010173A - Compuestos con actividad inductora de ferroptosis y métodos de uso. - Google Patents
Compuestos con actividad inductora de ferroptosis y métodos de uso.Info
- Publication number
- MX2021010173A MX2021010173A MX2021010173A MX2021010173A MX2021010173A MX 2021010173 A MX2021010173 A MX 2021010173A MX 2021010173 A MX2021010173 A MX 2021010173A MX 2021010173 A MX2021010173 A MX 2021010173A MX 2021010173 A MX2021010173 A MX 2021010173A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- inducing activity
- methods
- ferroptosis
- ferroptosis inducing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000004806 ferroptosis Effects 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/287,805 US11098040B2 (en) | 2018-02-28 | 2019-02-27 | Compounds and methods of use |
| PCT/US2019/019854 WO2019168999A1 (en) | 2018-02-28 | 2019-02-27 | Compounds with ferroptosis inducing activity and methods of their use |
| US201962893092P | 2019-08-28 | 2019-08-28 | |
| PCT/US2020/020150 WO2020176757A1 (en) | 2019-02-27 | 2020-02-27 | Compounds with ferroptosis inducing activity and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010173A true MX2021010173A (es) | 2021-12-10 |
Family
ID=72238937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010173A MX2021010173A (es) | 2019-02-27 | 2020-02-27 | Compuestos con actividad inductora de ferroptosis y métodos de uso. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3931183B1 (https=) |
| JP (1) | JP7704680B2 (https=) |
| KR (1) | KR20220012221A (https=) |
| CN (1) | CN114008024A (https=) |
| AU (1) | AU2020228056A1 (https=) |
| BR (1) | BR112021016833A2 (https=) |
| CA (1) | CA3131385A1 (https=) |
| EA (1) | EA202192122A1 (https=) |
| ES (1) | ES3013815T3 (https=) |
| IL (1) | IL285730A (https=) |
| MX (1) | MX2021010173A (https=) |
| SG (1) | SG11202109035QA (https=) |
| TW (1) | TW202045480A (https=) |
| WO (1) | WO2020176757A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| TW202000663A (zh) | 2018-02-28 | 2020-01-01 | 美商費洛醫療公司 | 化合物及使用方法 |
| US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
| TW202227399A (zh) * | 2020-08-26 | 2022-07-16 | 美商費洛醫療公司 | 化合物及使用方法 |
| KR102759930B1 (ko) * | 2022-01-17 | 2025-01-23 | 포항공과대학교 산학협력단 | Marh6(marchf6) 조절제를 포함하는, 페로토시스 조절용 조성물 및 방법 |
| WO2024015637A1 (en) * | 2022-07-15 | 2024-01-18 | Ferro Therapeutics, Inc. | Glutathione peroxidase 4 (gpx4) inhibitors for the treatment of cancer |
| CN114984019B (zh) * | 2022-07-15 | 2023-08-22 | 山东中医药大学 | 一种铁死亡抑制剂化合物及在肝损伤修复领域的应用 |
| CN117209521A (zh) * | 2022-11-04 | 2023-12-12 | 台州道致科技股份有限公司 | 丙炔酰氯制备方法 |
| CN116983310B (zh) * | 2023-08-29 | 2024-04-30 | 南方医科大学南方医院 | 一种治疗肝癌的药物组合物及其应用 |
| CN118047698A (zh) * | 2024-01-30 | 2024-05-17 | 山东科巢生物制药有限公司 | 一种n-[(1r)-2-[1,1'-联苯]-4-基-1-(羟基甲基)乙基]氨基甲酸叔丁酯的制备方法 |
| CN118994147B (zh) * | 2024-07-18 | 2026-01-02 | 中国海洋大学 | 一种基于疏水标签的gpx4蛋白降解剂及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03004023A (es) * | 2000-11-08 | 2004-02-12 | Lilly Icos Llc | Compuestos quimicos. |
| EP3791870A1 (en) * | 2013-12-02 | 2021-03-17 | The Trustees of Columbia University in the City of New York | Modulating ferroptosis and treating excitotoxic disorders |
| AU2016311426B2 (en) * | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
| US20190008961A1 (en) * | 2016-01-07 | 2019-01-10 | The Broad Institute, Inc. | Compounds and methods for increasing tumor infiltration by immune cells |
| WO2018118711A1 (en) * | 2016-12-19 | 2018-06-28 | The Trustees Of Columbia University In The City Of New York | Small molecule ferroptosis inducers |
| TW202000663A (zh) * | 2018-02-28 | 2020-01-01 | 美商費洛醫療公司 | 化合物及使用方法 |
| JP2023509359A (ja) * | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| CN113336748B (zh) * | 2021-04-12 | 2022-03-25 | 北京大学 | 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物 |
-
2020
- 2020-02-27 MX MX2021010173A patent/MX2021010173A/es unknown
- 2020-02-27 ES ES20712811T patent/ES3013815T3/es active Active
- 2020-02-27 EP EP20712811.7A patent/EP3931183B1/en active Active
- 2020-02-27 JP JP2021549973A patent/JP7704680B2/ja active Active
- 2020-02-27 WO PCT/US2020/020150 patent/WO2020176757A1/en not_active Ceased
- 2020-02-27 TW TW109106570A patent/TW202045480A/zh unknown
- 2020-02-27 CA CA3131385A patent/CA3131385A1/en active Pending
- 2020-02-27 BR BR112021016833A patent/BR112021016833A2/pt not_active Application Discontinuation
- 2020-02-27 EA EA202192122A patent/EA202192122A1/ru unknown
- 2020-02-27 KR KR1020217030619A patent/KR20220012221A/ko not_active Withdrawn
- 2020-02-27 AU AU2020228056A patent/AU2020228056A1/en not_active Abandoned
- 2020-02-27 CN CN202080028989.0A patent/CN114008024A/zh active Pending
- 2020-02-27 SG SG11202109035QA patent/SG11202109035QA/en unknown
-
2021
- 2021-08-19 IL IL285730A patent/IL285730A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220012221A (ko) | 2022-02-03 |
| JP7704680B2 (ja) | 2025-07-08 |
| AU2020228056A1 (en) | 2021-09-16 |
| BR112021016833A2 (pt) | 2021-11-23 |
| ES3013815T3 (en) | 2025-04-15 |
| CA3131385A1 (en) | 2020-09-03 |
| EA202192122A1 (ru) | 2021-12-15 |
| TW202045480A (zh) | 2020-12-16 |
| EP3931183B1 (en) | 2025-02-12 |
| EP3931183A1 (en) | 2022-01-05 |
| SG11202109035QA (en) | 2021-09-29 |
| IL285730A (en) | 2021-10-31 |
| WO2020176757A1 (en) | 2020-09-03 |
| JP2022522694A (ja) | 2022-04-20 |
| CN114008024A (zh) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MX2021000847A (es) | Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077. | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| WO2021041539A3 (en) | Pyrido-indole analogues as gpx4 inhibitors | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| MX376193B (es) | Compuestos para tratar el cancer cerebral. | |
| MX2024008461A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. |